Alvogen is a privately owned pharmaceutical company founded in 2009 with headquarters in the United States. Employing approximately 570 people, the company operates globally, engaging in the development, manufacturing, and sale of generic drugs, branded pharmaceuticals, over-the-counter medications, and biosimilars.
Alvogen Lux Holdings S.à r.l., the second-largest shareholder in Alvotech, acquired 95,000 Alvotech shares at ISK 1260 per share, according to a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF). A subsequent filing with the CSSF reported the acquisition of an additional 210,000 Alvotech shares at ISK 1277.38 per share by Alvogen Lux Holdings S.à r.l. Separately, Coherent Market Insights released a market assessment report on the Remicade Biosimilars Market, providing an analysis of market size, revenue, production, and CAGR. The report also details market trends, drivers, challenges, and the competitive landscape.
Subscribe for full access to Alvogen's products in full detail 
